New insight into the therapeutic role of the serotonergic system in Parkinson's disease

Progress in Neurobiology

Volumn 134, Issue , 2015, Pages 104-121

  Ohno, Yukihiro ^a   Shimizu, Saki ^a   Tokudome, Kentaro ^a   Kunisawa, Naofumi ^a   Sasa, Masashi ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 HT receptors; Clinical unmet needs; Extrapyramidal motor disorders; Non motor symptoms; Parkinson's disease; Serotonergic system

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLESINOXAN; GEPIRONE; IPSAPIRONE; LEVODOPA; PICLOZOTAN; SELEGILINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TALIPEXOLE; TANDOSPIRONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BASAL GANGLION; BRAIN CORTEX; CAUDATE NUCLEUS; CHOLINERGIC NERVE CELL; CLINICAL FEATURE; COGNITIVE DEFECT; CORPUS STRIATUM; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DYSKINESIA; FOREBRAIN; HEALTH CARE NEED; HIPPOCAMPUS; HUMAN; INTERNEURON; LEVODOPA-INDUCED DYSKINESIA; LIMBIC SYSTEM; MOOD DISORDER; MOTOR DYSFUNCTION; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; RAPHE NUCLEUS; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; ANIMAL; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; RECEPTORS, SEROTONIN; SEROTONIN AGENTS;

EID: 84947225648     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.09.005     Document Type: Review

References (225)

1. Aarsland D., Laake K., Larsen J.P., Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 2002, 72:708-712.
2. 1A receptor agonists on patterns of rat motor activity in relation to effects on forebrain monoamine synthesis. Pharmacol. Toxicol. 1993, 72:398-406.
3. Akhondzadeh S., Mohammadi N., Noroozian M., Karamghadiri N., Ghoreishi A., Jamshidi A.H., Forghani S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res. 2009, 107:206-212.
4. 1A receptor in anxiety disorders. Biol. Psychiatry 2009, 66:627-635.
5. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 2007, 113:296-320.
6. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
7. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 1995, 195:195-198.
8. 3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol. Aging 1997, 18:21-28.
9. 2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur. J. Neurosci. 1999, 11:2917-2934.
10. 3 receptor modulation of excitatory amino acid release in the rat nucleus tractus solitarius. Neurosci. Lett. 1995, 191:75-78.
11. Bakish D., Lapierre Y.D., Weinstein R., Klein J., Wiens A., Jones B., Horn E., Browne M., Bourget D., Blanchard A., Thibaudeau C., Waddell C., Raine D. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J. Clin. Psychopharmacol. 1993, 13:409-414.
12. 2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology 2011, 36:423-433.
13. 1A agonist in advanced Parkinson's disease. Mov. Disord. 2005, 20:932-936.
14. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol. Biochem. Behav. 1990, 35:955-962.
15. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
16. Baumgarten H.G., Grozdanovic Z. Psychopharmacology of central serotonergic systems. Pharmacopsychiatry 1995, 28:73-79.
17. Benitez A., Edens H., Fishman J., Moran K., Asgharnejad M. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Ann. N. Y. Acad. Sci. 2014, 1329:45-66.
18. Bergman J., Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin. Neuropharmacol. 2002, 25:107-110.
19. 2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr. Scand. 1991, 83:244-248.
20. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. 2006, 23:77-86.
21. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013, 28:1088-1096.
22. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
23. h by 5-HT receptors in mouse CA1 hippocampal neurons. Eur. J. Neurosci. 2002, 16:209-218.
24. 1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 2009, 87:1645-1658.
25. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987, 1:470-480.
26. 1A agonists in the treatment of depression?. Biol. Psychiatry 2003, 53:193-203.
27. Boast C., Bartolomeo A.C., Morris H., Moyer J.A. 5-HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol. Learn. Mem. 1999, 71:259-271.
28. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res. 2011, 221:564-573.
29. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17:73-82.
30. 7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 2007, 32:1840-1854.
31. 6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol. 1998, 125:1562-1566.
32. Bronzova J., Sampaio C., Hauser R.A., Lang A.E., Rascol O., Theeuwes A., van de Witte S.V., van Scharrenburg G., Bruegel Study Group Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov. Disord. 2010, 25:738-746.
33. Carta M., Bezard E. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 2011, 198:245-251.
34. Carta M., Tronci E. Serotonin system implication in l-DOPA-induced Dyskinesia: from animal models to clinical investigations. Front. Neurol. 2014, 5:78.
35. Ceglia I., Carli M., Baviera M., Renoldi G., Calcagno E., Invernizzi R.W. The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J. Neurochem. 2004, 91:189-199.
36. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991, 5:219-229.
37. Chartoff E.H., Ward R.P., Dorsa D.M. Role of adenosine and N-methyl-d-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J. Pharmacol. Exp. Ther. 1999, 291:531-537.
38. 2A receptors are increased in Parkinson's disease neocortex. Ann. N. Y. Acad. Sci. 1998, 861:288-289.
39. Cheshire P.A., Williams D.R. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J. Clin. Neurosci. 2012, 19:343-348.
40. 4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 1994, 5:1230-1232.
41. Cummings J., Isaacson S., Mills R., Williams H., Chi-Burris K., Corbett A., Dhall R., Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014, 383:533-540.
42. 3 receptor. Curr. Opin. Pharmacol. 2011, 11:75-80.
43. 2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J. Psychiatr. Res. 2008, 42:894-901.
44. Del Tredici K., Braak H. Dysfunction of the locus-coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J. Neurol. Neurosurg. Psychiatry 2013, 84:774-783.
45. 1A antipsychotic compounds. Eur. J. Pharmacol. 2008, 597:34-38.
46. 1A receptor agonists. Eur. Neuropsychopharmacol. 2010, 20:641-654.
47. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., Ashby C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 1995, 15:821-829.
48. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 2005, 25:10831-10843.
49. 2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci. 2008, 28:2933-2940.
50. Dougherty J.P., Oristaglio J. Chronic treatment with the serotonin 2A/2C receptor antagonist SR 46349B enhances the retention and efficiency of rule-guided behavior in mice. Neurobiol. Learn. Mem. 2013, 103:50-63.
51. 1A agonist ipsapirone prevents ethanol-associated death of total rhombencephalic neurons and prevents the reduction of fetal serotonin neurons. Dev. Brain Res. 2004, 150:79-88.
52. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry 1993, 163:451-455.
53. 1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl.) 2008, 199:99-108.
54. Ehrt U., Broich K., Larsen J., Ballard C., Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J. Neurol. Neurosurg. Psychiatry 2010, 81:160-165.
55. Elliott P.J., Walsh D.M., Close S.P., Higgins G.A., Hayes A.G. Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology 1990, 29:949-956.
56. 1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
57. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord. 2007, 22:1379-1389.
58. 1A anxiolytics: an overview. Psychopathology 1989, 22:21-26.
59. 2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 2010, 59:31-36.
60. 2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease. Neurochem. Int. 2014, 71:36-46.
61. 4 receptor ligands in rat spatial navigation. Neuropharmacology 1997, 36:689-696.
62. 3 receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. Methods Find. Exp. Clin. Pharmacol. 2004, 26:615-622.
63. 4 receptors in the mouse passive avoidance test. J. Pharmacol. Exp. Ther. 1998, 286:1115-1121.
64. Gallagher D.A., Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol. Dis. 2012, 46:581-589.
65. Gaspar P., Gray F. Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta Neuropathol. 1984, 64:43-52.
66. 1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl.) 1988, 94:178-182.
67. Gil-Bea F.J., Domínguez J., García-Alloza M., Marcos B., Lasheras B., Ramírez M.J. Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation. Neuropharmacology 2004, 47:225-232.
68. Giovannini M.G., Ceccarelli I., Molinari B., Cecchi M., Goldfarb J., Blandina P. Serotonergic modulation of acetylcholine release from cortex of freely moving rats. J. Pharmacol. Exp. Ther. 1998, 1285:1219-1225.
69. 1A receptor agonist. Synapse 2006, 60:599-608.
70. Godbout R., Chaput Y., Blier P., de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology 1991, 30:679-690.
71. Goldman J.G., Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr. Treat. Options Neurol. 2014, 16:281.
72. Greffard S., Verny M., Bonnet A.M., Beinis J.Y., Gallinari C., Meaume S., Piette F., Hauw J.J., Duyckaerts C. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 2006, 63:584-588.
73. Grégoire L., Samadi P., Graham J., Bédard P.J., Bartoszyk G.D., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkinsonism Relat. Disord. 2009, 15:445-452.
74. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400.
75. 2A/C receptor ligands in a delay-based decision-making task in rats. Behav. Pharmacol. 2009, 20:415-423.
76. Hadrava V., Blier P., Dennis T., Ortemann C., de Montigny C. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology 1995, 34:1311-1326.
77. Halliday G.M., Li Y.W., Blumbergs P.C., Joh T.H., Cotton P.R., Howe P.R., Blessing W.W., Geffen L.B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 1990, 27:373-385.
78. Halliday G.M., Leverenz J.B., Schneider J.S., Adler C.H. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov. Disord. 2014, 29:634-650.
79. Hauser R.A., Bronzova J., Sampaio C., Lang A.E., Rascol O., Theeuwes A., van de Witte S.V., Pardoprunox Study Group Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur. Neurol. 2009, 62:40-48.
80. Hely M.A., Morris J.G., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., Broe G.A., Margrie S. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol. Neurosurg. Psychiatry 1994, 57:903-910.
81. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4:600-609.
82. 2 receptor antagonist, on Parkinson's disease. Clin. Exp. Neurol. 1992, 29:277-282.
83. Hirose A., Sasa M., Akaike A., Takaori S. Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997. Neuropharmacology 1990, 29:93-101.
84. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 2006, 553:109-119.
85. 3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl.) 1996, 125:146-161.
86. 1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav. Brain Res. 2011, 220:83-90.
87. 2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 2010, 25:1399-1408.
88. 1A receptors in the MPTP-lesioned macaque. Neurobiol. Aging 2012, 33:207.
89. Huot P., Fox S.H. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp. Brain Res. 2013, 230:463-476.
90. Hussain N., Flumerfelt B.A., Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001, 102:391-399.
91. 1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat. Exp. Neurol. 2015, 271:335-350.
92. Ishibashi T., Ikeda K., Ishida K., Yasui J., Tojima R., Nakamura M., Ohno Y. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur. J. Pharmacol. 1996, 303:247-251.
93. 1A agonist, tandospirone, in rats. Biog. Amines 2004, 8:329-338.
94. 3H]acetylcholine release from rat striatal slices. Gen. Pharmacol. 1996, 27:1203-1207.
95. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572:160-170.
96. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 1992, 72:165-229.
97. 3 receptors in vagal reflex inputs to neurones in the nucleus tractus solitarius of anaesthetized rats. J. Physiol. 2005, 566:939-953.
98. 1A receptor agonist with efficacy in experimental models of Parkinson's disease. Eur. Neuropsychopharmacol. 2010, 20:582-593.
99. 1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 2002, 54:133-137.
100. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 2001, 52:503-517.
101. 1A agonistic anxiolytic. Neuropharmacology 1991, 30:475-480.
102. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., Ravert H.T., Dannals R.F., Hilton J., Wong D.F., Szabo Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 2003, 60:1223-1229.
103. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47:195-204.
104. 6 receptors in learning and memory. Trends Pharmacol. Sci. 2008, 29:482-492.
105. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
106. 1A receptor. Neuropsychopharmacology 2006, 31:101-111.
107. 1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 2001, 420:103-112.
108. Koller W.C., Hutton J.T., Tolosa E., Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999, 53:1012-1019.
109. 1A receptors. Mol. Brain Res. 2004, 129:104-116.
110. 4 receptors. Neuropharmacology 2001, 41:844-853.
111. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 2005, 30:2169-2179.
112. 1A receptors. Br. J. Pharmacol. 2010, 160:1929-1940.
113. 1A receptor expression during memory formation. Psychopharmacology (Berl.) 2005, 181:309-318.
114. 1A receptors in spatial and aversive learning in the rat. Neuropharmacology 2005, 48:830-852.
115. 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J. Pharmacol. Exp. Ther. 2006, 316:581-591.
116. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005, 1046:230-233.
117. 6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res. 2010, 7:374-385.
118. Maher-Edwards G., Dixon R., Hunter J., Gold M., Hopton G., Jacobs G., Hunter J., Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int. J. Geriatr. Psychiatry 2011, 26:536-544.
119. 1B/1D agonist rizatriptan: update on recent research and implications for the future. Expert Opin. Pharmacother. 2008, 9:1001-1011.
120. 6 receptor-mediated acetylcholine release. Eur. J. Neurosci. 2006, 24:1299-1306.
121. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 2006, 1112:126-133.
122. 1A receptor activation in mice. Eur. J. Pharmacol. 1995, 280:235-238.
123. McDonald W.M., Richard I.H., DeLong M.R. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol. Psychiatry 2003, 54:363-375.
124. Meireles J., Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front. Neurol. 2012, 3:88.
125. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 1991, 17:263-287.
126. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21:106S-115S.
127. 1A receptors improve cognition in schizophrenia?. Behav. Brain Res. 2008, 195:98-102.
128. 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010, 35:881-892.
129. Meltzer H.Y., Roth B.L. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J. Clin. Invest. 2013, 123:4986-4991.
130. Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev. Neurosci. 2013, 24:629-664.
131. 1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl.) 2002, 163:85-94.
132. Miguelez C., Morera-Herreras T., Torrecilla M., Ruiz-Ortega J.A., Ugedo L. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front. Neural Circuits 2014, 8:21.
133. Milber J.M., Noorigian J.V., Morley J.F., Petrovitch H., White L., Ross G.W., Duda J.E. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012, 79:2307-2314.
134. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005, 60:441-460.
135. 1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 2003, 28:253-264.
136. 6 receptor-mediated mechanism. Neuropharmacology 2006, 50:412-420.
137. 6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology 2007, 32:1520-1530.
138. 6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol. Biochem. Behav. 2008, 88:291-298.
139. 1A receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models. Neurobiol. Dis. 2013, 59:244-256.
140. 4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 2007, 53:563-573.
141. 6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology (Berl.) 2012, 220:687-696.
142. 1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
143. 1A receptors in rats. Pharmacol. Rep. 2010, 62:258-264.
144. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 1993, 265:207-217.
145. 1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr. Opin. Investig. Drugs 2010, 11:802-812.
146. 1 agonist RU 24969 and effects on dopaminergic behaviour. Eur. J. Pharmacol. 1987, 139:205-214.
147. 2 receptor antagonist, using the mouse pole test. Pharmacol. Biochem. Behav. 1994, 49:19-23.
148. 1A agonist, on activities of the lateral septal nucleus neurons in cats. Serotonin in the Central Nervous System and Periphery 1995, 159-165. Elsevier Science BV, Amsterdam. Y. Takada, G. Curzon (Eds.).
149. 2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol. J. Pharmacol. 1997, 49:213-219.
150. Ohno Y. Tandospirone Citrate. A New Serotonergic Anxiolytic Agent: A Potential use in Parkinson's Disease. Mapping the Progress of Alzheimer's and Parkinson's DISEASE 2002, 423-428. Kluwer Academic/Plenum, New York. Y. Mizuno, A. Fisher, A. Hanin (Eds.).
151. 1A agonists using the mouse pole test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1302-1307.
152. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., Kawai Y. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55:717-723.
153. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J. Pharmacol. Sci. 2009, 109:593-599.
154. 1A receptors in central nervous system disorders. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10:148-157.
155. 1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci. Ther. 2011, 17:58-65.
156. 6 receptors. Neuropharmacology 2011, 60:201-208.
157. Ohno Y., Tatara A., Shimizu S., Sasa M. Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors. Schizophrenia Research: Recent Advances 2012, 321-335. Nova Science Publishers, New York. T. Sumiyoshi (Ed.).
158. Ohno Y., Shimizu S., Tokudome K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol. Pharm. Bull. 2013, 36:1396-1400.
159. 1A receptors in learning and memory. Behav. Brain Res. 2008, 195:54-77.
160. 1A receptor agonist 8-OH-DPAT. Eur. J. Pharmacol. 1998, 358:147-152.
161. 1A receptor stimulation. Neuropharmacology 2011, 61:753-760.
162. 1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res. 2005, 321:159-172.
163. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10734-10739.
164. 1A and CB2 receptors. Neuropharmacology 2013, 71:282-291.
165. Pifl C., Kish S.J., Hornykiewicz O. Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov. Disord. 2012, 27:1618-1624.
166. Poewe W., Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:S28-S32.
167. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-221.
168. Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., Bain P., Molloy S., Piccini P. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J. Clin. Invest. 2014, 124:1340-1349.
169. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol. 2002, 453:217-221.
170. 1A receptor: a representative member of the serotonin receptor family. Cell Mol. Neurobiol. 2005, 25:553-580.
171. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14476-14481.
172. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 2000, 342:1484-1491.
173. 1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res. 2004, 1030:201-220.
174. 1A receptor: G protein coupling and signalling pathways. Br. J. Pharmacol. 1999, 127:1751-1764.
175. 2C receptor antagonist. Br. J. Pharmacol. 1999, 126:572-574.
176. Richard I.H., Schiffer R.B., Kurlan R. Anxiety and Parkinson's disease. J. Neuropsychiatr. Clin. Neurosci. 1996, 8:383-392.
177. Roth B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry 1994, 6:67-78.
178. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol. 2000, 129:1028-1034.
179. 2 antagonists modulates the effects of D2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 1990, 253:1162-1170.
180. Samii A., Nutt J.G., Ransom B. Parkinson's disease. Lancet 2004, 363:1783-1793.
181. Sarnyai Z., Sibille E.L., Pavlides C., Fenster R.J., McEwen B.S., Toth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin1A receptors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14731-14736.
182. Schechter L.E., Bolaños F.J., Gozlan H., Lanfumey L., Haj-Dahmane S., Laporte A.M., Fattaccini C.M., Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J. Pharmacol. Exp. Ther. 1990, 255:1335-1347.
183. 6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33:1323-1335.
184. Scheller D., Ullmer C., Berkels R., Gwarek M., Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379:73-86.
185. Schmidt C.J., Lovenberg W. In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neurosci. Lett. 1985, 59:9-14.
186. 1A receptor antagonists. Eur. J. Pharmacol. 1994, 271:537-541.
187. 2C receptors. Neuropharmacology 1994, 33:467-471.
188. Shimizu H., Tatsuno T., Tanaka H., Hirose A., Araki Y., Nakamura M. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn. J. Pharmacol. 1992, 59:105-112.
189. 1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:877-881.
190. 1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:86-91.
191. 1A receptors. Aging Dis. 2013, 4:1-13.
192. Shimizu S., Mizuguchi Y., Sobue A., Fujiwara M., Morimoto T., Ohno Y. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. J. Pharmacol. Sci. 2015, 127:439-445.
193. 3 receptor antagonists on neuroleptic-induced catalepsy in mice. Neuropharmacology 1995, 34:97-99.
194. 4 receptor modulation of acetylcholine outflow in guinea pig brain slices. Neuroreport 1999, 10:547-551.
195. 2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
196. Somola N. Dopaminergic treatments for Parkinson's disease: light and shadows. Emerging Drugs and Targets for Parkinson's Disease 2013, 61-82. RSC Publishing, Cambridge. A. Mattinez, C. Gil (Eds.).
197. 1A receptors and pharmacotherapy is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?. Psychopharmacol. Bull. 1994, 30:39-43.
198. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol. 2000, 163:239-243.
199. Stefański R., Pałejko W., Kostowski W., Płaźnik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992, 31:1251-1258.
200. Strecker K., Wegner F., Hesse S., Becker G.A., Patt M., Meyer P.M., Lobsien D., Schwarz J., Sabri O. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J. Neurol. 2011, 258:19-26.
201. Styte S., Vissel B. Advances in non-dopaminergic treatments for Parkinson's disease. Front. Neurosci. 2014, 8:113-151.
202. Suchanek B., Struppeck H., Fahrig T. The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis. Eur. J. Pharmacol. 1998, 355:95-101.
203. 1A agonist, on memory function in schizophrenia. Biol. Psychiatry 2001, 49:861-868.
204. 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2007, 95:158-168.
205. 6 receptor stimulation. J. Neurosci. 2007, 27:4201-4209.
206. Svenningsson P., Rosenblad C., Af Edholm Arvidsson K., Wictorin K., Keywood C., Shankar B., Lowe D.A., Björklund A., Widner H. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain 2015, 138:963-973.
207. 1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J. Pharmacol. Exp. Ther. 1999, 288:843-848.
208. Tatara A., Shimizu S., Shin N., Sato M., Sugiuchi T., Imaki J., Ohno Y. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:252-259.
209. Tayarani-Binazir K., Jackson M.J., Rose S., McCreary A.C., Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp. Neurol. 2010, 226:320-327.
210. 3 receptor pharmacology. Trends Pharmacol. Sci. 2013, 34:100-109.
211. 1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. 2005, 52:185-194.
212. Törk I. Anatomy of the serotonergic system. Ann. N. Y. Acad. Sci. 1990, 600:9-34.
213. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl.) 1989, 98:45-50.
214. 1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br. J. Pharmacol. 1992, 106:893-899.
215. 2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav. 2008, 90:540-544.
216. 6 with neuropeptides in rat striatum. J. Comp. Neurol. 1996, 370:405-414.
217. 1A agonists measured with the forced swim test. Psychopharmacology (Berl.) 1990, 101:497-504.
218. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210-219.
219. 6 receptor antagonist Ro 04-6790. Psychopharmacology (Berl.) 2003, 170:358-367.
220. 6 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:59-79.
221. Xu Y., Yan J., Zhou P., Li J., Gao H., Xia Y., Wang Q. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2012, 97:1-13.
222. Yarnall A., Rochester L., Burn D.J. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov. Disord. 2011, 26:2496-2503.
223. 1A dual-agonist profile. J. Med. Chem. 2011, 54:4324-4338.
224. Zhang Z.J., Kang W.H., Li Q., Wang X.Y., Yao S.M., Ma A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 2006, 88:102-110.
225. Zweig R.M., Cardillo J.E., Cohen M., Giere S., Hedreen J.C. The locus ceruleus and dementia in Parkinson's disease. Neurology 1993, 43:986-991.